Inventiva shares fall 7.5% over the week and slip back below their 20-day moving average (MM20)
The Burgundy-based biotech specializing in fibrotic and metabolic diseases eases off in mid-morning trading, in a Paris market that is declining alongside Wall Street and Asia. The stock interrupts the rebound under way since late October.
A pullback that brings the stock back below its short-term averages
Inventiva shares fell 2.38% to €3.08, while the SBF 120 lost 0.99% following a lower close on Wall Street. The stock is now below its 20-day moving average (MM20: €3.31, a gap of 7.10%) and its 50-day moving average (MM50: €3.16), while the RSI at 44 remains neutral.
After gaining more than 20% over one month, the stock has lost 7.66% over seven days and ranks among the lowest performers in the index.
The support at €2.65 is 14% below the current price, and the resistance at €3.59 is 17% above. The MACD, at 0.0407 versus 0.0622 for its signal line, remains below the latter, consistent with the slowdown of the rebound.
Cash consolidated in spring, no revenue in the first half
When the H1 2026 results were published (on 29 July 2026), Inventiva had recorded no revenue, compared with €4.5 million a year earlier.
The group also stated that its cash position did not cover operating requirements for the next twelve months without additional financing, with visibility limited to the end of the second quarter of 2027. On 2 June 2026, it had announced a €103 million capital increase and a €75 million financing transaction, of which tranche C may bring in up to €20 million. The next scheduled event is the publication of third-quarter revenue, expected on 23 November.